课题基金 / 基金详情

项目摘要

项目成果

Alan Thomas Remaley的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In the past year, we completed a Phase I clinical trial of LCAT. The study was done at the NIH and was a single dose escalation study in 18 subjects. There was no significant adverse events and the the recombinant LCAT behaved like expected based on animal studies in regard to its ability to modulate HDL metabolism. We also commenced a long-term animal toxicity study in collaboration with AlphaCore Pharma, our CRADA partner and plan to file IND early next year to begin a clinical trial treating patients with a genetic deficiency of LCAT. We are also planning on doing a clinical study on monitoring the flux of cholesterol after recombinant LCAT treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development Of New Assays For Lipoprotein Testing
  • 批准号:
    6675216
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Alan Thomas Remaley
  • 依托单位:
Development of recombinant Lecithin Cholesterol Acyltransferase as a therapeutic
Use Of Animal Models To Study Genes That Modulate Atherosclerosis
Development and Diagnostic Use of Rapid Immunoassays
  • 批准号:
    6227890
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Alan Thomas Remaley
  • 依托单位:
国内基金
海外基金
基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
  • 批准号:
    82302715
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    熊泽康
  • 依托单位:
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2021
  • 负责人:
    陈英伟
  • 依托单位:
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
  • 批准号:
    31200592
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    孙伟力
  • 依托单位: